Ixodes ricinus-Contact Phase Inhibitor Promotes Functional Recovery and Attenuates Neutrophil Associated Neuroinflammation After Experimental Intracerebral Hemorrhage.

Authors

Stéphanie Demoulin, Annelise Letourneur, Florent Lebrun, Nicolas Violle, Denis Vivien, Valérie Pireaux

Published in

CNS neuroscience & therapeutics. Volume 32. Issue 11.

Abstract

Neutrophil-associated inflammation contributes to secondary brain injury after intracerebral hemorrhage (ICH). We evaluated whether Ixodes ricinus-Contact Phase Inhibitor (Ir-CPI), a selective factor XIa/XIIa inhibitor with reported thromboinflammatory modulatory properties, improves outcome after experimental ICH without worsening bleeding.
In a collagenase-induced mouse ICH model, Ir-CPI was administered as an intravenous bolus followed by a 3-day infusion. Vehicle animals served as controls and enoxaparin as an anticoagulant comparator. Cohorts evaluated hemorrhage and lesion volumes, endothelial activation, neutrophil-associated inflammation, and longitudinal functional recovery. Ir-CPI association with human neutrophils was evaluated in vitro.
Ir-CPI did not increase hemorrhage or lesion volumes versus PBS through Day 14, whereas enoxaparin showed a higher Day 1 hemorrhage volume than Ir-CPI. Flow cytometry showed Ir-CPI association with human neutrophils. In the mouse model, Ir-CPI produced region-specific reductions in neutrophil infiltration and NET formation and reduced neuronal degeneration at the injection site and caudal level, without affecting VCAM-1-associated endothelial activation. Ir-CPI accelerated functional recovery, improving neurological scores and sensorimotor asymmetry by Day 5, with restoration of baseline corner test performance by Day 14.
Ir-CPI improves recovery after experimental ICH without exacerbating bleeding and is associated with reduced neutrophil-associated secondary brain injury. These findings support its translational potential as a therapeutic strategy for ICH.

PMID:
42963926
Bibliographic data and abstract were imported from PubMed on 31 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.